© 2019 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon

Helomics® Corporation Announces the appointment of Dr. Marc Malandro to its Advisory Board, providing strategic insights for the Skyline Medical – Helomics Joint Venture.

January 8, 2018

 

 

PITTSBURGH–January 4, 2018- Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, today announced the addition of Marc Malandro PhD, CLP, RTTP, currently Vice President of Operations for Science at the Chan Zuckerberg Initiative, to its Advisory Board. The addition of Dr. Malandro provides significant scientific and business expertise to Helomics as well as Helomics’ recently announced joint venture with Skyline Medical Inc (NASDAQ: SKLN) to build-out and commercialize the Helomics D-CHIP™ platform

Marc Malandro, PhD, CLP, RTTP was the founding director of the Innovation Institute and Vice Chancellor for Technology Management and Commercialization at the University of Pittsburgh. Dr. Malandro was responsible for leading the combination of the Office of Technology Management, the Office of Enterprise Development and the Institute for Entrepreneurial Excellence forming the Pitt Innovation Institute in 2013. Prior to The University of Pittsburgh, Dr. Malandro, who has a doctoral degree in biochemistry and molecular biology from the University of Florida, co-founded Sagres Discovery, a California-based systems biology company focused on the understanding of the molecular basis of cancer.

Marc S. Malandro, PhD, CLP, RTTP, commented, “I am delighted to be able to provide my insights and experience to help Helomics, an innovative Pittsburgh-grown company, as it executes its new strategy to use the rich data accumulated on patients with cancer to build out their D-CHIP™ platform.”

D-CHIP™ uses an AI-powered bioinformatics platform that combines drug response profiles from patient tumors along with molecular, genomic, biochemical and histopathology data with de-identified patient data. The actionable insights generated by D-CHIP will have a meaningful impact in precision medicine for the development of new therapies and diagnostics.”

“We are very fortunate to have such a talented and accomplished industry leader such as Dr. Malandro on our Advisory Board,” stated Gerald J. Vardzel Jr., President and CEO of Helomics. “The scientific and business experience that Marc brings to us will be invaluable to our build –out and commercialization efforts of our D-CHIP™ platform.”

 

 “As personalized medicine continues to evolve by tailoring therapies to an individual patient’s molecular data, it is critical to assemble the right industry experts to lead the way, having Dr. Malandro on our advisory team is a huge asset.” commented Mark Collins, Ph.D., Vice President of Innovation and Strategy at Helomics.

 

 


Gerald J. Vardzel Jr.

President & CEO

 

Helomics Corporation

91 43RD Street, Suite 220

Pittsburgh, PA 15201

 

Office: +1-412-432-1500

Mobile: +1-843-725-9574

Email: gvardzel@helomics.com

 

Facebook | Twitter | Pinterest | LinkedIn | G+

 

www.helomics.com

 

 

 

 

 

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

September 10, 2019

1/10
Please reload

Recent Posts
Please reload

Archive